Evidence map›Paper›PMID 41176773›Full record

ArticleChemistryOpen2026

Design, Synthesis, Cytotoxicity Assessment, and Molecular Docking of Novel Triazolopyrimidines as Potent Cyclin-Dependent Kinase 4 Inhibitors.

Tariq Z Abolibda, Sami A Al-Hussain, Basant Farag, Mohamed El-Naggar, Magdi E A Zaki, Emad S A Alhazmi, Adel S M Almohammadi, Sobhi M Gomha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tariq Z AbolibdaDepartment of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah, 42351, Saudi.
Sami A Al-HussainDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
Basant FaragDepartment of Chemistry, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt.
Mohamed El-NaggarDepartment of Chemistry, Pure and Applied Chemistry Group, Faculty of Sciences, University of Sharjah, Sharjah, 27272, UAE.
Magdi E A ZakiDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
Emad S A AlhazmiMedical Center, Islamic University of Madinah, Madinah, 42351, Saudi Arabia.
Adel S M AlmohammadiMedical Center, Islamic University of Madinah, Madinah, 42351, Saudi Arabia.
Sobhi M GomhaDepartment of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah, 42351, Saudi.ORCID 0000-0002-7739-2837

Funding

Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU) IMSIU-DDRSP2501
6 · The paper itself

Abstract

Cyclin-dependent kinase 4 (CDK4) plays a pivotal role in cell cycle regulation and is a well-established target in cancer therapy. Triazolopyrimidines, as bioactive heterocyclic compounds, represent a promising scaffold for the development of novel anticancer agents. Herein, a new series of 1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine derivatives (5a-g) is synthesized via multistep reactions involving 6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl propionate and hydrazonoyl halides. Structural confirmation is achieved through infrared spectroscopy,

Indexed as

Antineoplastic AgentsCyclin-Dependent Kinase 4Drug DesignMolecular Docking SimulationProtein Kinase InhibitorsPyrimidinesTriazolesCell ProliferationDrug Screening Assays, AntitumorHep G2 CellsHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCDK4 protein, humanCyclin-Dependent Kinase 4Protein Kinase InhibitorsPyrimidinesTriazoles1,2,4‐triazolo[4,3‐a]pyrimidinesabsorption, distribution, metabolism, excretion, and toxicityantitumor activitycyclin‐dependent kinase 4hydrazonoyl halidesmolecular docking

Identifiers

PMID41176773
PMCPMC13052328

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.